Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
6
Bullish
5
Bearish
18
Neutral
18
Bullish
10
Bearish
15
Neutral
12
Bullish
5
Bearish
3
Neutral
6
Bullish
5
Bearish
3
Neutral
6
Bullish
5
Bearish
15
Neutral
12
Bullish
5
Bearish
15
Neutral
12
Bullish
5
Bearish
15
Neutral
12
Bullish
5
Investor Presentation
Q1 FY27
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Healthcare Equipment & Supplies
Medical Equipment & Supplies
178 Cr
Low Risk
20.3
56.6
—
2.0
414.95
222.00
Sales CAGR
Profit CAGR
ROE
ROCE
Avience Biomedicals Ltd (AVIENCE) is currently trading at 323.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Avience Biomedicals Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, Avience Biomedicals Ltd has traded between a low of ₹222.00 and a high of ₹414.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Avience Biomedicals Ltd has a market capitalization of approximately 177.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Avience Biomedicals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.30 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 177.58 Cr, Avience Biomedicals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Avience Biomedicals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Avience Biomedicals Ltd is 20.30. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The price band was ₹196 to ₹208 per share, and the IPO price was fixed at ₹208 per share.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
102.00 | 194 Cr | 38.08 | 2.80 | 0.00 | 7.35 | 14.27 | 6.24 | ||
130.00 | 179 Cr | 36.27 | 2.76 | 0.00 | 7.67 | 12.12 | 7.09 | ||
323.75 | 178 Cr | 20.27 | 1.96 | 0.00 | 27.86 | 23.21 | 11.24 | ||
205.05 | 117 Cr | 22.52 | 3.18 | 0.00 | 12.67 | 18.00 | 10.94 | ||
65.00 | 92 Cr | 13.87 | 1.69 | 0.00 | 12.17 | 15.03 | 8.36 | ||
185.00 | 69 Cr | 21.41 | 3.90 | 0.00 | 17.36 | 22.18 | 12.60 | ||
72.40 | 63 Cr | 27.13 | 2.38 | 0.00 | 8.76 | 11.99 | 6.93 | ||
| Median: 7 Co. | — | 130.00 | 117 Cr | 22.52 | 2.76 | 0.00 | 12.17 | 15.03 | 8.36 |
Public Notice/Press Release
Avience Biomedicals Ltd participated in the Arihant Bharat Connect Conference (Rising Star) on 2026-09-30 from 15:00 to 16:00 IST via virtual mode; management interacted with investors/analysts and confirmed no UPSI was shared.
AGM/EGM Notice
Avience Biomedicals submitted voting results and the Scrutinizer's Report for its 7th AGM held on 2026-09-30 via VC/OAVM; documents are available on the company website and CDSL.
AGM/EGM Notice
Avience Biomedicals Ltd held its 7th AGM on 30-09-2026 via VC; members adopted audited standalone and consolidated financials for FY ended 31-03-2026, approved reappointments, auditors, borrowing limit up to ₹100 Cr and other statutory items.
Regulatory/Compliance Filing
Avience Biomedicals Ltd informed that at the AGM on 2026-09-30 it appointed M/s M.A.M and Associates as statutory auditors (replacing M/s Haribhakti & Co. LLP) and also appointed secretarial and internal auditors.
